CoChat
Sign Up
Cited by 9

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice

Stukas, Sophie, Freeman, Lita, Lee, Michael, Wilkinson, Anna, Ossoli, Alice, Vaisman, Boris, Demosky, Stephen, Chan, Jeniffer, Hirsch-Reinshagen, Veronica, Remaley, Alan T., Wellington, Cheryl L.·2014·Journal of Lipid Research
DOI 10.1194/jlr.m049940
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.m049940

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 37

  1. Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science., 261, 921, 10.1126/science.8346443 · DOI · Paper page
  2. Stukas, 2014, High density lipoproteins and cerebrovasular integrity in Alzheimer's disease, Cell Metab., 19, 574, 10.1016/j.cmet.2014.01.003 · DOI
  3. Strittmatter, 1993, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proc. Natl. Acad. Sci. USA., 90, 1977, 10.1073/pnas.90.5.1977 · DOI · Paper page
  4. Schmechel, 1993, Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease, Proc. Natl. Acad. Sci. USA., 90, 9649, 10.1073/pnas.90.20.9649 · DOI · Paper page
  5. Polvikoski, 1995, Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein, N. Engl. J. Med., 333, 1242, 10.1056/NEJM199511093331902 · DOI · Paper page
  6. Holtzman, 2000, Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model, Ann. Neurol., 47, 739, 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8 · DOI
  7. Irizarry, 2000, Modulation of A beta deposition in APP transgenic mice by an apolipoprotein E null background, Ann. N. Y. Acad. Sci., 920, 171, 10.1111/j.1749-6632.2000.tb06919.x · DOI · Paper page
  8. Bales, 1999, Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. USA., 96, 15233, 10.1073/pnas.96.26.15233 · DOI · Paper page
  9. Fryer, 2003, Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice, J. Neurosci., 23, 7889, 10.1523/JNEUROSCI.23-21-07889.2003 · DOI · Paper page
  10. Holtzman, 2000, Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. USA., 97, 2892, 10.1073/pnas.050004797 · DOI · Paper page
  11. Fagan, 2002, Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease, Neurobiol. Dis., 9, 305, 10.1006/nbdi.2002.0483 · DOI · Paper page
  12. Fryer, 2005, Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model, J. Neurosci., 25, 2803, 10.1523/JNEUROSCI.5170-04.2005 · DOI · Paper page
  13. Sagare, 2012, Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease, Cold Spring Harb. Perspect. Med., 2, a011452, 10.1101/cshperspect.a011452 · DOI · Paper page
  14. Verghese, 2013, ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions, Proc. Natl. Acad. Sci. USA., 110, E1807, 10.1073/pnas.1220484110 · DOI · Paper page
  15. Hirsch-Reinshagen, 2004, Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain, J. Biol. Chem., 279, 41197, 10.1074/jbc.M407962200 · DOI · Paper page
  16. Wahrle, 2004, ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE, J. Biol. Chem., 279, 40987, 10.1074/jbc.M407963200 · DOI · Paper page
  17. Aiello, 2003, ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation, Arterioscler. Thromb. Vasc. Biol., 23, 972, 10.1161/01.ATV.0000054661.21499.FB · DOI
  18. Wahrle, 2005, Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease, J. Biol. Chem., 280, 43236, 10.1074/jbc.M508780200 · DOI · Paper page
  19. Fan, 2011, An ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from glia, J. Lipid Res., 52, 1605, 10.1194/jlr.M014365 · DOI · Paper page
  20. Pitas, 1987, Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain, J. Biol. Chem., 262, 14352, 10.1016/S0021-9258(18)47945-8 · DOI · Paper page
  21. Koch, 2001, Characterization of four lipoprotein classes in human cerebrospinal fluid, J. Lipid Res., 42, 1143, 10.1016/S0022-2275(20)31605-9 · DOI · Paper page
  22. Demeester, 2000, Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease, J. Lipid Res., 41, 963, 10.1016/S0022-2275(20)32039-3 · DOI · Paper page
  23. Rousset, 2011, Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?, Curr. Atheroscler. Rep., 13, 249, 10.1007/s11883-011-0171-6 · DOI
  24. Ng, 1997, Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I, J. Biol. Chem., 272, 15777, 10.1074/jbc.272.25.15777 · DOI
  25. Sakai, 1997, Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency, J. Biol. Chem., 272, 7506, 10.1074/jbc.272.11.7506 · DOI
  26. Hirsch-Reinshagen, 2009, LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins, J. Lipid Res., 50, 885, 10.1194/jlr.M800584-JLR200 · DOI · Paper page
  27. Albers, 1992, Lecithin cholesterol acyltransferase in human cerebrospinal fluid: reduced level in patients with multiple sclerosis and evidence of direct synthesis in the brain, Int. J. Clin. Lab. Res., 22, 169, 10.1007/BF02591418 · DOI
  28. DeMattos, 2002, Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease, J. Neurochem., 81, 229, 10.1046/j.1471-4159.2002.00889.x · DOI
  29. Vaisman, 1995, Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice, J. Biol. Chem., 270, 12269, 10.1074/jbc.270.20.12269 · DOI
  30. Vaisman, 2013, Measurement of lecithin-cholesterol acyltransferase activity with the use of a Peptide-proteoliposome substrate, Methods Mol. Biol., 1027, 343, 10.1007/978-1-60327-369-5_16 · DOI
  31. Yesilaltay, 2006, Effects of hepatic expression of the high-density lipoprotein receptor SR-BI on lipoprotein metabolism and female fertility, Endocrinology., 147, 1577, 10.1210/en.2005-1286 · DOI
  32. Freeman, 2013, Western blots, Methods Mol. Biol., 1027, 369, 10.1007/978-1-60327-369-5_18 · DOI
  33. Han, 2011, Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy, Mol. Neurodegener., 6, 86, 10.1186/1750-1326-6-86 · DOI
  34. Lefterov, 2010, Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice, J. Biol. Chem., 285, 36945, 10.1074/jbc.M110.127738 · DOI
  35. Calabresi, 2009, Functional LCAT is not required for macrophage cholesterol efflux to human serum, Atherosclerosis., 204, 141, 10.1016/j.atherosclerosis.2008.08.038 · DOI
  36. Kay, 2003, Remodeling of cerebrospinal fluid lipoprotein particles after human traumatic brain injury, J. Neurotrauma., 20, 717, 10.1089/089771503767869953 · DOI
  37. Namjoshi, 2013, The liver X receptor agonist GW3965 improves recovery from mild repetitive traumatic brain injury in mice partly through apolipoprotein E, PLoS ONE., 8, e53529, 10.1371/journal.pone.0053529 · DOI

Cited by

Sorted by citations

Metadata

Authors
Stukas, S., Freeman, L., Lee, M., Wilkinson, A., Ossoli, A., Vaisman, B., Demosky, S., Chan, J., Hirsch-Reinshagen, V., Remaley, A. T., & Wellington, C. L.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2014-08
Volume
55
Issue
8
Pages
1721-1729
ISSN
0022-2275
DOI
10.1194/jlr.m049940
Cited by
9
References
21
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review